The Grady Liver Clinic - Atlanta, GA United States

The Grady Liver Clinic - Atlanta, GA United States

Virus targets
Hepatitis C
Type
Testing and treatment implementation
Setting
Sub-National
Phase
Active
Health outcomes
Prevalence
WHO region
Region of the Americas
Country
United States of America
Key interventions
Persons who inject drugs: HCV cure as prevention
Strategic data analysis
Screening and diagnosis
Treatment (direct or referral)
Target population
Birth cohorts of adults
Performance target
Care cascade: Evidence of current infection
Care cascade: HCV diagnosis
Care cascade: HCV testing
Care cascade: HCV treatment
Care cascade: Referred for treatment
If you would like to have a program page for your program, please create an account and submit program information here

Health outcomes additional info

25% reduction in HCV prevalence by 2022

Performance target additional info

HCV Testing: Test 90% of baby boomers by 2021; HCV diagnosis: Test 99% of HCV Ab + patients for HCV RNA by 2021; Referred for treatment: Refer 90% of eligible patients for HCV treatment by 2021; HCV Treatment: Achieve >95% cure rate among those who initiate treatment and are tested for cure by 2021

Summary and objectives

The Grady Liver Clinic (GLC) has become a model of excellence for non-traditional approaches to hepatitis C care, as it provides access for patients with healthcare disparities. Founded in 2002, the GLC is based at Grady Memorial Hospital, part of a safety-net health system in Atlanta, GA. The GLC is an innovative model for HCV care in that it is primary care-based and staffed by general internists with expertise in HCV management. Using a multidisciplinary team approach including physicians, clinical pharmacists, nurses and patient navigators and a coordinator, the GLC has successfully implemented large scale hepatitis C screening and linkage to care as well as treatment programs. We have tested almost 34,000 patients for hepatitis C, revealed a 9% prevalence of infection, and we currently treat approximately 500 patients annually with a 98% cure rate.